Allium Medical promotes CFO to CEO
This article was originally published in Clinica
Executive Summary
Allium Medical (Caesarea, Israel), a developer and manufacturer of removable stents specially designed for the urinary and gastro-intestinal tract (see Medtech Ventures No 18 in Clinica No 1299) has promoted Limor Domnitz Gishri to CEO. Her successor as CFO is yet to be decided. Formerly CFO and vice-president of business, Ms Domnitz Gishri will now lead the company’s strategic growth plans. Her background is in law and accounting, where she specialised in advanced technologies and biotech. She currently combines her business responsibilities with lecturing in business and accounting at Tel Aviv University and College. Allium says Ms Domnitz Gishri has helped transform the company over two years from an R&D firm to a sales and distribution company.
You may also be interested in...
Asia Regulatory Forum Update
Three upcoming medical device regulations were discussed at BSI’s Hong Kong Forum in April that will be important to the success of Hong Kong’s voluntary regulatory system, the Medical Device Administrative Control System.
Saudi Arabia adopts interim device authorisation regulation
Saudi Arabia has adopted an interim marketing authorisation regulation under which, possibly as early as 2010, only medical devices that have been approved by the Saudi Arabia Food and Drug Administration will be allowed on the market1. Additionally, only medical devices that comply with the regulations in force in the European Union, the US, Canada, Japan or Australia – ie in the jurisdiction of a Global Harmonization Task Force founding member - will be eligible for marketing in the country2,3.
Canada takes action to increase more adverse event reporting
The government of Canada has launched a marketing campaign to encourage consumers and healthcare professionals to use the country’s MedEffect initiative for reporting suspected adverse events related to healthcare products1.